Aspire Biopharma, Inc. Announces Newly Appointed Medical Advisory Board Members

HUMACAO, PR, September 5, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of three new members to its Medical Advisory Board.

Aspire Biopharma, Inc. is excited to announce the addition of three new highly qualified advisors to its Medical Advisory Board, including Morhaf Abrahim, M.D., an Electrophysiologist and Cardiologist and Founder and President of Ibrahim Heart Clinic in Jacksonville, FL Gary, C. Bernard, M.D., President and CEO of Pointe Medical Services, Inc. in Jacksonville, FL, and  John A. Mansour, Jr., D.O., Chief of Orthopedic Surgery for The Hughston Clinic at HCA Florida Orange Park Hospital. The biographical information on each of the newly appointed Medical Advisory Board Members can be found on the Company’s website in the investor relations section:

Kraig Higginson, Executive Chairman, stated, “On behalf of the Board and entire management team, we’d like to thank our new Medical Advisors for joining us for this revolutionary journey and quest for delivering revolutionary drug delivery solutions to improve patient care and save lives.”

About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit

Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward- looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.